Why the Prostate's Transition Zone Causes BPH Symptoms

The prostate is not a uniform organ — it is divided into distinct anatomical zones with different functions, different cell types, and crucially, different susceptibility to disease. Understanding which zone is responsible for BPH explains why the symptoms are specifically urinary, why they develop in the pattern they do, and why certain treatments target specific areas.

The Four Zones of the Prostate

• •Peripheral zone (70% of prostate volume): Located at the back of the gland, palpable on digital rectal exam. This is where most prostate cancers originate. Not typically involved in BPH.
• •Central zone (25% of volume): Surrounds the ejaculatory ducts. Rarely involved in either BPH or cancer.
• •Transition zone (a small share of prostate volume in young men): Surrounds the urethra directly. This is where BPH mainly originates [1].
• •Anterior fibromuscular stroma: No glandular tissue — smooth muscle and fibrous tissue only.

Why the Transition Zone Causes BPH

The transition zone is where BPH nodules form and keep growing as a man ages. This growth is thought to be driven largely by dihydrotestosterone (DHT) — a potent derivative of testosterone produced by the enzyme 5-alpha reductase [2][3]. As the transition zone enlarges with age, it compresses the urethra that passes through its centre. Because the urethra is surrounded by the transition zone, any expansion inward directly reduces the urethral lumen.

The Three Mechanisms of Obstruction

• •Static obstruction: The physical bulk of BPH tissue mechanically compresses the urethra — reduceable with 5-ARI medications (finasteride, dutasteride) that shrink the gland.
• •Dynamic obstruction: Smooth muscle in the transition zone and prostate capsule contracts under alpha-adrenergic stimulation, reducing urethral diameter. Treatable with alpha-blockers (tamsulosin) within days.
• •Bladder compensation and decompensation: The bladder muscle thickens to overcome obstruction (compensation), then eventually weakens (decompensation) — causing incomplete emptying independent of prostate size.

Why Prostate Size Does Not Always Correlate With Symptoms

A clinically important counter-intuitive fact: the transition zone can enlarge substantially into the interior of the prostate (intravesical growth into the bladder base) or outward laterally — with very different symptom profiles. A man with a 60g prostate growing laterally may have minimal IPSS symptoms, while a man with a 30g prostate with significant intravesical growth (median lobe, discussed separately) may have severe obstruction.

DHT and the Transition Zone: The Hormonal Driver

Dihydrotestosterone (DHT) is produced from testosterone by the enzyme 5-alpha reductase type 2, which is expressed at high levels specifically in the transition zone. DHT binds to androgen receptors in transition zone stromal cells with greater affinity than testosterone itself. This creates a DHT-sensitive environment that persists throughout a man's life — unlike the peripheral zone, which downregulates androgen sensitivity after puberty. The result is continuous, age-related growth that accelerates after 50.

• •DHT concentrations are high in the transition zone
• •5-alpha reductase type 2 inhibitors (finasteride) substantially reduce intraprostatic DHT
• •Dutasteride inhibits both type 1 and type 2 5-alpha reductase, reducing DHT even more deeply
• •Transition zone volume is reduced with finasteride over many months of therapy
• •Men with naturally lower DHT levels (5-alpha reductase deficiency) do not develop BPH — confirming DHT's causative role
• •Dietary factors that reduce 5-alpha reductase activity include saw palmetto extract and zinc-rich foods

Transition Zone Growth Patterns and Their Symptoms

The transition zone can expand in two anatomical directions — each producing a different clinical picture. Lateral lobe enlargement compresses the urethra from the sides, creating a narrowed channel with weak stream and hesitancy as the primary complaints. Median lobe growth (also called intravesical protrusion) extends upward into the bladder base, obstructing the bladder outlet like a ball-valve mechanism. Median lobe BPH produces more severe obstruction at smaller prostate volumes and responds less predictably to medications than lateral lobe disease.

Monitoring the Transition Zone Over Time

PSA (prostate-specific antigen) correlates strongly with inner zone volume — roughly 0.1 ng/mL per gram of benign prostate tissue. A man with a PSA of 4.0 and a negative biopsy likely has approximately 40 grams of benign transition zone growth. This is why urologists use PSA as a surrogate marker for prostate size when ultrasound is not immediately available. Annual PSA testing therefore serves two purposes: cancer screening and inner zone volume monitoring.

How the Transition Zone Causes BPH Symptoms

The transition zone wraps directly around the prostatic urethra — the section of urethra that passes through the prostate gland. As transition zone nodules enlarge, they compress the urethra from all sides, increasing urethral resistance. The bladder must then generate higher pressure to overcome this resistance, initially causing symptom-free compensation (detrusor hypertrophy). Over years, the bladder muscle fatigues, detrusor contractility decreases, and symptoms become permanent: weak stream, hesitancy, incomplete emptying, and eventually — if untreated — acute urinary retention or chronic retention with upper tract damage.

• •Transition zone volume >30mL — 5-ARIs (finasteride, dutasteride) indicated alongside alpha-blockers
• •Transition zone volume >60mL — consider UroLift candidacy evaluation; TURP or HoLEP may be first choice
• •Transition zone volume >80mL — HoLEP (holmium laser enucleation) preferred over standard TURP for complete removal
• •Transition zone nodular pattern — responds less predictably to medication than diffuse uniform enlargement
• •PSA density = total PSA ÷ total prostate volume — a density of 0.15 or more has been used as a trigger to consider biopsy, but it indicates higher risk rather than cancer [4]

Transition Zone vs. Peripheral Zone: Different Roles in Disease

The prostate has two main functional zones. The transition zone (inner gland) surrounds the urethra and is the primary site of BPH — it enlarges throughout a man's life under DHT influence. The peripheral zone (outer gland) makes up about 70% of prostate volume in young men and is the primary site of prostate cancer — most cancers arise here. This anatomical distinction has clinical implications: BPH symptoms are caused by transition zone growth; elevated PSA from BPH reflects transition zone inflammation and compression; prostate cancer in the peripheral zone may not cause urinary symptoms until advanced. A man can have significant inner-zone BPH with limited peripheral zone abnormality — and vice versa.